ArriVent BioPharma Analyst Price Targets - Benzinga

ArriVent BioPharma Inc

AVBPNASDAQ

Trade with Public

Trade with Public

$15.95

0.221.4%

最終更新: Oct 30, 6:08 AM

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

ArriVent BioPharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for ArriVent BioPharma (AVBP).

Price Target Range — 12 Quarters

Analyst Consensus — 12 Analysts

12Buy

Consensus RatingBuy# Analysts12Avg. Consensus PT$33Upside to Avg. PT+107.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 27, 2026	Guggenheim	Michael Schmidt	PT Raise	Buy	$18→$30
Oct 20, 2026	B. Riley Securities	Kalpit Patel	PT Cut	Buy	$45→$29
Oct 16, 2026	BTIG	Jeet Mukherjee	Maintained	Buy	$29
Oct 8, 2026	HC Wainwright & Co.	Robert Burns	PT Cut	Buy	$47→$27
Oct 7, 2026	Citigroup	Yigal Nochomovitz	PT Cut	Buy	$40→$20
Oct 7, 2026	Jones Trading	Soumit Roy	PT Cut	Buy	$45→$22
Oct 7, 2026	Truist Securities	Supawat Thongthip	PT Cut	Buy	$45→$18
Oct 7, 2026	Guggenheim	Michael Schmidt	PT Cut	Buy	$45→$18
Oct 7, 2026	BTIG	Jeet Mukherjee	PT Cut	Buy	$42→$29
Aug 17, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$44→$47
Aug 13, 2026	Citigroup	Yigal Nochomovitz	PT Cut	Buy	$43→$40
Aug 13, 2026	Guggenheim	Michael Schmitz	Maintained	Buy	$45
Aug 13, 2026	BTIG	Jeet Mukherjee	Maintained	Buy	$42
May 29, 2026	Truist Securities	Supawat Thongthip	PT Raise	Buy	$43→$45
May 13, 2026	Citigroup	Yigal Nochomovitz	PT Cut	Buy	$45→$43
Apr 24, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$33→$45
Mar 23, 2026	B. Riley Securities	Kalpit Patel	PT Raise	Buy	$37→$45
Mar 12, 2026	BTIG	Jeet Mukherjee	Assumes	Buy	$42
Mar 6, 2026	Oppenheimer	Jeff Jones	PT Raise	Outperform	$44→$50
Mar 6, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$31→$33

Analyst Ratings News

PRO
Guggenheim Maintains Buy on ArriVent BioPharma, Raises Price Target to $30

Guggenheim analyst Michael Schmidt maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price target from $18 to $30.

Benzinga Newsdesk

PRO
B. Riley Securities Maintains Buy on ArriVent BioPharma, Lowers Price Target to $29

B. Riley Securities analyst Kalpit Patel maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $45 to $29.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on ArriVent BioPharma, Maintains $29 Price Target

BTIG analyst Jeet Mukherjee reiterates ArriVent BioPharma (NASDAQ:AVBP) with a Buy and maintains $29 price target.

Benzinga Newsdesk

Eli Lilly To Rally Over 21%? Here Are 10 Top Analyst Forecasts For Thursday

Analysts raised targets for Everpure, Eli Lilly and Delek US, while cutting targets for Constellation, Tyler, ArriVent and Netflix.

Avi Kapoor

PRO
HC Wainwright & Co. Maintains Buy on ArriVent BioPharma, Lowers Price Target to $27

HC Wainwright & Co. analyst Robert Burns maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $47 to $27.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on ArriVent BioPharma, Lowers Price Target to $20

Citigroup analyst Yigal Nochomovitz maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $40 to $20.

Benzinga Newsdesk